Free press releases distribution network?

Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Most of the Marketed Monoclonal Antibodies Lack a Patent Protection in India Finds IMARC Group - Biosimilar manufacturers are currently free to copy and manufacture most of the globally marketed therapeutic monoclonal antibodies in India - IMARCgroup.com
Most of the Marketed Monoclonal Antibodies Lack a Patent Protection in India Finds IMARC Group

 

PRZOOM - /newswire/ - Noida, Uttar Pradesh, India, 2012/01/24 - Biosimilar manufacturers are currently free to copy and manufacture most of the globally marketed therapeutic monoclonal antibodies in India - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IMARC Group, one of the world’s leading research and advisory firms, in its new report entitled “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016”, finds that unlike the developed markets such as the US and Europe; most of the current marketed monoclonal antibodies are not protected by a patent in India. The report provides a comprehensive analysis on the patent position of all the in–market monoclonal antibodies in India, US and Europe. Details such as patentee name, patent number, patent status and estimated patent expiries of all in-market monoclonal antibodies have been thoroughly analyzed in the report. Findings from the report suggested that out of all the globally marketed monoclonal antibodies only three are currently protected by a patent in India. As a result, biosimilar manufacturers are free to copy and manufacture most of the globally marketed monoclonal antibodies in the country.

IMARC’s new report entitled “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” provides an analytical and statistical insight into the Indian Antibodies market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of the following aspects of the Indian antibodies market.

Key Aspects Analyzed:

Diagnostic Antibodies
Understanding the strengths, weaknesses, opportunities and challenges in the Indian diagnostic antibodies market
Understanding the technological considerations and regulatory factors in the Indian diagnostic antibodies market
• Evaluating the various types of antibody based diagnostic tests conducted in India and analyzing their strengths and weaknesses.
• Understanding the key regulations for registering, manufacturing and importing diagnostics in India.

Comprehensive situation analysis of the Indian diagnostic antibodies market
Segments covered: HIV, Hepatitis B, Hepatitis C, Tuberculosis, Dengue, Syphilis and Oncology

Focus of the analysis in each segment:
• Number of tests conducted each year;
• Breakup by type of tests conducted;
• Current and future market sales;
• Average cost of diagnostic tests;
• Key players operating in the market.

Therapeutic Antibodies
Understanding the strengths, weaknesses, opportunities and challenges in the Indian therapeutic antibodies market
Understanding the technological considerations and regulatory factors in the Indian therapeutic antibodies market
• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act.
• Understanding the key regulations for registering, manufacturing and importing therapeutic antibodies in India.

Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe.
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe.

Comprehensive situation analysis of the Indian therapeutic antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroad

Table of Contents
1 Market Definitions & Methodology

2 Executive Summary

3 Indian Antibodies Market

4 Antibody Based Diagnostics Market in India
4.1 Industry Analysis
4.1.1 Strengths
4.1.2 Weaknesses
4.1.3 Opportunities
4.1.4 Threats
4.2 Technological & Regulatory Assessment
4.2.1 Technological Assessment
4.2.2 Regulatory Assessment
4.3 Market Analysis
4.3.1 Current & Future Sales Trends
4.3.2 Market Segments by Usage
4.3.2.1 HIV Diagnostics: Current Trends & Forecast
4.3.2.2 Hepatitis B Diagnostics: Current Trends & Forecast
4.3.2.3 Hepatitis C Diagnostics: Current Trends & Forecast
4.3.2.4 Tuberculosis Diagnostics: Current Trends & Forecast
4.3.2.5 Dengue Diagnostics: Current Trends & Forecast
4.3.2.6 Pregnancy Diagnostics: Current Trends & Forecast
4.3.2.7 Syphilis Diagnostics: Current Trends & Forecast
4.3.2.8 Oncology Diagnostics: Current Trends & Forecast

5 Therapeutic Antibodies Market in India
5.1 Industry Analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2 Technological & Regulatory Assessment
5.2.1 Technological Assessment
5.2.2 Regulatory Assessment
5.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India
5.4 Market Analysis
5.4.1 Current & Future Sales Trends
5.4.2 Sales Breakup by Molecule
5.4.3 Sales by Indication
5.5 Evaluation of Top Monoclonal Antibodies
5.5.1.1 Avastin
5.5.1.2 Herceptin
5.5.1.3 Rituxan/Mabthera
5.5.1.4 Remicade
5.5.1.5 Humira
5.6 Biosimilar Case Studies
5.6.1 Reditux
5.6.2 Grafeel
5.7 Key Indian & Foreign Biosimilar Antibody Development Programmes.

To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
E: apac[.]imarcgroup.com / P: +91-120-425-6531

IMARC Group North America
E: america[.]imarcgroup.com / P: +1-631-791-1145

To know more please visit imarcgroup.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Most of the Marketed Monoclonal Antibodies Lack a Patent Protection in India Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today